RESEARCH & DEVELOPMENT
Pipeline
Recro Pharma is currently developing a number of compounds for the adjunctive management of severe, intractable pain, as well as the treatment of breakthrough pain (BTP).
January 2010:
DEX-TD Phase I Clinical
Study initiated.
December 2009:
William Ashton joins Board
of Directors.
September 2009:
DEX-SL Phase I Clinical Study initiated in the U.S.
